Prazepam
Centrax (prazepam) is a small molecule pharmaceutical. Prazepam was first approved as Centrax on 1982-01-01. It is used to treat alcohol withdrawal delirium, anxiety disorders, duodenal ulcer, muscle spasticity, and partial epilepsies in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| alcohol withdrawal delirium | EFO_1000800 | D000430 | — |
| anxiety disorders | EFO_0006788 | D001008 | F41.1 |
| duodenal ulcer | EFO_0004607 | D004381 | K26 |
| muscle spasticity | HP_0001257 | D009128 | — |
| partial epilepsies | EFO_0004263 | D004828 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
412 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 11 | 20 | 8 | 2 | 2 | 39 | |
| Septic shock | D012772 | A48.3 | 1 | 7 | 12 | 5 | 4 | 26 | |
| Adrenal insufficiency | D000309 | 4 | 3 | 3 | 8 | 3 | 20 | ||
| Sepsis | D018805 | A41.9 | — | 4 | 6 | 3 | 7 | 19 | |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | 6 | — | 5 | 3 | 15 |
| Congenital adrenal hyperplasia | D000312 | E25.0 | 4 | 7 | 2 | 3 | 1 | 15 | |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 2 | — | 3 | 9 | 14 |
| Healthy volunteers/patients | — | 5 | 1 | 1 | 2 | — | 9 | ||
| Addison disease | D000224 | E27.1 | 1 | 5 | 1 | 1 | 3 | 9 | |
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | 2 | 3 | 1 | — | 7 |
Show 38 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | C95 | 1 | 12 | 10 | — | 2 | 24 | |
| Prostatic neoplasms | D011471 | C61 | 2 | 11 | 5 | — | 1 | 17 | |
| Lymphoma | D008223 | C85.9 | — | 6 | 6 | — | — | 12 | |
| Myeloid leukemia acute | D015470 | C92.0 | 6 | 3 | 2 | — | — | 10 | |
| Myelodysplastic syndromes | D009190 | D46 | 3 | — | 3 | — | — | 6 | |
| Heart arrest | D006323 | EFO_0009492 | I46 | 2 | 2 | 2 | — | 2 | 6 |
| Covid-19 | D000086382 | U07.1 | — | — | 2 | — | 3 | 5 | |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 3 | — | 1 | 4 |
| Bronchopulmonary dysplasia | D001997 | P27.8 | — | 2 | 2 | — | — | 4 | |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 2 | 1 | — | 2 | 4 |
Show 35 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 1 | — | — | 2 | 4 |
| Hemorrhoids | D006484 | EFO_0009552 | K64 | — | 3 | — | — | 1 | 4 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | 2 | — | — | 1 | 3 |
| Neoplasms | D009369 | C80 | — | 3 | — | — | — | 3 | |
| Burkitt lymphoma | D002051 | C83.7 | 1 | 3 | — | — | — | 3 | |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 3 | — | — | — | 3 |
| Essential tremor | D020329 | EFO_0003108 | G25.0 | — | 3 | — | — | — | 3 |
| Biphenotypic leukemia acute | D015456 | C95.0 | — | 2 | — | — | — | 2 | |
| Head and neck neoplasms | D006258 | — | 1 | — | — | 1 | 2 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | 1 | 2 |
Show 46 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 3 | — | — | — | 2 | 5 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 2 | — | — | — | — | 2 |
| Hematologic neoplasms | D019337 | 1 | — | — | — | 1 | 2 | ||
| Blood pressure | D001794 | EFO_0004325 | 2 | — | — | — | — | 2 | |
| T-cell lymphoma | D016399 | 2 | — | — | — | — | 2 | ||
| Insulin resistance | D007333 | EFO_0002614 | 1 | — | — | — | 1 | 2 | |
| Cocaine-related disorders | D019970 | F14 | 1 | — | — | — | 1 | 2 | |
| Infections | D007239 | EFO_0000544 | 1 | — | — | — | 1 | 2 | |
| Recurrence | D012008 | 2 | — | — | — | — | 2 | ||
| T-cell lymphoma peripheral | D016411 | C84.9 | 1 | — | — | — | — | 1 |
Show 22 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | — | 3 | 3 |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | — | 2 | 2 | |
| Pituitary diseases | D010900 | E23.7 | — | — | — | — | 1 | 1 | |
| Circadian rhythm sleep disorders | D020178 | G47.2 | — | — | — | — | 1 | 1 | |
| Hypopituitarism | D007018 | EFO_0001380 | E23.0 | — | — | — | — | 1 | 1 |
| Fever | D005334 | HP_0001945 | R50.9 | — | — | — | — | 1 | 1 |
| Orthostatic hypotension | D007024 | I95.1 | — | — | — | — | 1 | 1 | |
| Hypothermia | D007035 | HP_0002045 | T68 | — | — | — | — | 1 | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | — | 1 | 1 |
| Esophageal stenosis | D004940 | K22.2 | — | — | — | — | 1 | 1 |
Show 37 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PRAZEPAM |
| INN | prazepam |
| Description | Prazepam is a benzodiazepine derivative drug developed by Warner-Lambert in the 1960s. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Prazepam is a prodrug for desmethyldiazepam which is responsible for the therapeutic effects of prazepam.
|
| Classification | Small molecule |
| Drug class | antianxiety agents (diazepam type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1 |
Identifiers
| PDB | — |
| CAS-ID | 2955-38-6 |
| RxCUI | 8627 |
| ChEMBL ID | CHEMBL969 |
| ChEBI ID | 8362 |
| PubChem CID | 4890 |
| DrugBank | DB01588 |
| UNII ID | Q30VCC064M (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 311 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
504 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more